Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: existence (36), time (1000), living (489), days (1000), years (986)

BEACOPP escalated

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP Escalated) Re
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-escalated.pdf

BEACOPP 14

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP-14) Regimen •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-14.pdf

BEACOPDac escalated

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DACARBAZINE-DOXORUBICIN-ETOPOSIDEPREDNISOLONE-VINCRISTINE (BEACOPDac Escalated) R
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPDac-escalated.pdf

Pembrolizumab Ver 1 skin

Description: Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf

Bevacizumab ver 1

Description: Chemotherapy Protocol CNS CANCER BEVACIZUMAB This protocol may require funding. This is an unlicensed indication for bevacizumab. Regimen CN
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CNS/Bevacizumab-ver-1.pdf

Delusions erode capacity

Description: A recent case provides a rare explicit example of how delusions can be relevant in compromising a person's capacity.
Url: /HealthProfessionals/Clinical-law-updates/Delusions-erode-capacity.aspx

Featured research: ImmunoCOVID19 study

Description: Auto Generated Title Psychological sub-study (added 04/08/2021) For the past year you have kindly provided us with information on ho
Url: /ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-ImmunoCOVID19-study.aspx

RFC_PO

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA RFC-CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO) Regimen • CLL – RFC (PO)-Cyclophosphami
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO.pdf

RFC_PO_Split

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO-Split) Regimen • CLL – RFC (PO)-Cyclophospha
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO-Split.pdf

RFC_IV

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (IV) Regimen • CLL – RFC (IV)-Cyclophosphamide-F
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-IV.pdf

281 to 290 of 1000

Previous … 27 28 29 30 31 … Next